Spectral AI names Prof. Paul Chadwick, Former CEO of the Royal College of Podiatry UK, as Senior Executive for UK and EMEA
2023年10月24日 - 9:00PM
Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the
“Company”), an artificial intelligence (AI) company
focused on medical diagnostics for faster and more accurate
treatment decisions in wound care, today announced the appointment
of Prof. Paul Chadwick as Executive Vice President of the Company’s
United Kingdom subsidiary. Prof. Chadwick is an experienced
clinical scientist and wound care key opinion leader (KOL) with an
impressive body of work including a substantial and impactful
publication record, particularly in the domain of diabetic wound
management. He will be responsible for the international market
expansion of the Company’s DeepView® wound imaging technology in
the United Kingdom, Europe, Middle East and Africa (EMEA), all of
which are geographic areas where Prof. Chadwick has extensive
clinical networks, significant experience and has enjoyed previous
successes.
“Paul brings over fifteen years of invaluable
expertise in the medical devices and technology sectors to our
team. The Royal College of Podiatry is an extremely prestigious and
important organization where Paul most recently served for over six
years in senior executive capacities, including CEO. We are highly
confident that his addition will significantly enhance our efforts
in advancing the widespread adoption of the DeepView® System,” said
Niko Pagoulatos, the Company’s COO. “Spectral AI continues to
strengthen its leadership team and Paul’s experience in diabetic
foot ulcers and clinical wound management will contribute to our
growth and enhance our capacity to innovate.”
Prof. Chadwick’s impressive journey stretches
across clinical, academic and business disciplines. In his previous
roles at the Royal College of Podiatry, Prof. Chadwick led all the
clinical, educational and financial aspects of the organization. In
addition, he has held multiple leadership positions such as
consultant podiatrist at The National Health Service (NHS), and
Managing Director at Curativo Wound Care Consultancy, where he has
served companies such as 3M, Molnlycke Health Care, Smith &
Nephew, Advancis, Thornton & Ross, Essity and many others. In
his capacity as a prominent authority in wound care, Prof. Chadwick
fulfills critical roles on advisory boards and exemplifies best
practices in the field. Furthermore, he generously imparts his
knowledge as an adjunct professor at Birmingham City University,
where he teaches in the Health and Life Sciences Department.
Prof. Chadwick said, “Coming from a traditional
wound care background with an emphasis on DFU and other chronic
wounds, and having collaborated with leading commercial
organizations in the wound care arena at a national and global
level, with a focus on EMEA, I am delighted to contribute to
Spectral AI’s mission and success, and I believe that the DeepView®
System represents the future of wound healing management. As we
move forward, this technology has the potential to transform
patient wound care at multiple levels.”
Prof. Chadwick earned his Ph.D. with a thesis on
aspects of painful diabetic neuropathy at the University of
Salford. He earned his M.Sc. with a focus on foot ulceration from
Manchester Metropolitan University and holds an undergraduate
degree in Science Honors from the University of Brighton.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive
AI company focused on medical diagnostics for faster and more
accurate treatment decisions in wound care, with initial
applications involving patients with burns and diabetic foot
ulcers. The Company is working to revolutionize the management of
wound care by “Seeing the Unknown®” with its DeepView® System.
DeepView® is a predictive diagnostic device that offers
clinicians an objective and immediate assessment of a wound’s
healing potential prior to treatment or other medical intervention.
With algorithm-driven results and a goal of substantially exceeding
the current standard of care in the future, DeepView® is
expected to provide faster and more accurate treatment insight
towards value care by improving patient outcomes and reducing
healthcare costs. For more information about DeepView®,
visit www.spectral-ai.com.
Forward Looking Statements
Certain statements made in this release are
“forward looking statements” within the meaning of the “safe
harbor” provisions of the United States Private Securities
Litigation Reform Act of 1995, including statements regarding the
Company’s strategy, plans, objectives, initiatives and financial
outlook. When used in this press release, the words “estimates,”
“projected,” “expects,” “anticipates,” “forecasts,” “plans,”
“intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,”
“propose” and variations of these words or similar expressions (or
the negative versions of such words or expressions) are intended to
identify forward-looking statements.
These forward-looking statements are not
guarantees of future performance, conditions or results, and
involve a number of known and unknown risks, uncertainties,
assumptions and other important factors, many of which are outside
Company’s control, that could cause actual results or outcomes to
differ materially from those discussed in the forward-looking
statements. As such, readers are cautioned not to place undue
reliance on any forward-looking statements.
Investors should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” sections of the Company’s filings with the
SEC, including the Registration Statement and the other documents
filed by the Company. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements.
Contacts:
Investors:Spectral AI,
Inc.Christine Marks VP Marketing and Commercialization
ir@spectral-ai.com
The Equity Group Devin Sullivan Managing
Director dsullivan@equityny.com
Conor Rodriguez Analyst crodriguez@equityny.com
Media: Russo Partners David
Schull Russo Partners (858) 717-2310
david.schull@russopartnersllc.com
Guillermo Ruiz, M.D., Ph.D. Russo Partners (646) 218-4604
guillermo.ruiz@russopartnersllc.com
Spectral AI (NASDAQ:MDAI)
過去 株価チャート
から 5 2024 まで 6 2024
Spectral AI (NASDAQ:MDAI)
過去 株価チャート
から 6 2023 まで 6 2024